secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001297184-23-000079
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15
------------------------------------------------------------------

- Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).
- GAAP net income $49.2M ($0.91 diluted EPS) vs $15.9M ($0.30) a year ago.
- Adjusted non-GAAP net income $61.9M ($1.15 diluted EPS) vs $20.2M ($0.38).
- CEO attributes growth to diabetes portfolio, including BAQSIMI acquisition and generic glucagon.
- Nine-month net revenues $466.3M vs $364.0M; GAAP net income $101.4M vs $57.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/0001297184-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/amph-20231108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer